Início › Sobrepeso › Arizona › Tucson
Ensaios clínicos de Sobrepeso em Tucson, AZ
15 estudos para Sobrepeso estão buscando participantes em locais em Tucson e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
RecrutandoFase 3
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RecrutandoFase 3
- University of Arizona, Tucson
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RecrutandoFase 3
- Tucson Clinical Research Institute, Tucson
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
RecrutandoFase 3
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
RecrutandoFase 3
- Research Site, Tucson
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RecrutandoFase 3
- Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
RecrutandoFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
RecrutandoFase 3
- AURORA-1 Clinical Site, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
RecrutandoFase 3
- AURORA-2 Clinical Site, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
RecrutandoFase 3
- Arizona Clinical Trials, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
RecrutandoFase 3
- Arizona Clinical Trials, Tucson
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
RecrutandoFase 3Voluntários saudáveis bem-vindos
- ACCOMPLISH-2 Research Site, Tucson
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RecrutandoFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RecrutandoFase 2
- Pima Heart, Tucson
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
RecrutandoFase 3
- ACCOMPLISH-1 Research Site, Tucson
Ensaios de Sobrepeso em outras cidades
- San Antonio, TX34 estudos
- Houston, TX33 estudos
- Chicago, IL28 estudos
- Orlando, FL27 estudos
- Las Vegas, NV23 estudos
- Miami, FL23 estudos
- Atlanta, GA20 estudos
- Dallas, TX20 estudos
- New York City, NY19 estudos
- Jacksonville, FL19 estudos
- Washington, DC19 estudos
- Austin, TX18 estudos
Outros estudos em Tucson
- Câncer de Mama20 estudos
- Câncer de Pulmão de Não Pequenas Células17 estudos
- Obesidade17 estudos
- Câncer Metastático14 estudos
- Câncer (todos os tipos)12 estudos
- Doença Cardiovascular12 estudos
- Câncer Colorretal11 estudos
- Câncer de Próstata11 estudos
- Doença Hepática Esteatótica10 estudos
- Insuficiência Cardíaca10 estudos
- Pressão Alta10 estudos
- Diabetes tipo 210 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.